Axogen (AXGN) Q2 FY26 earnings call

Axogen delivered strong Q2 FY26 results, driven by robust demand for Avance, particularly in the Breast market, and effective sales force expansion. The company raised its full-year revenue guidance, reflecting confidence in its commercial execution and market development strategies. While gross margin faced near-term pressure from product mix, management is implementing pricing and production efficiency initiatives to address this, maintaining a positive long-term outlook for profitability and market expansion.